Radiofrequency hyperthermia (RFH) increases local tumor temperature and may enhance sensitivity to systemic therapies. We evaluated the association between adding RFH to first-line immune checkpoint inhibitor (ICI) plus chemotherapy and outcomes in patients with HER2-negative advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma. This study adopted a single-center, retrospective, observational design. Patients treated between January 2021 and January 2024 were retrospectively enrolled and grouped by receipt of RFH (hyperthermia vs. non-hyperthermia). The primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety. A 1:1 propensity score matching (PSM) analysis was performed. A total of 212 patients were included: 119 in the hyperthermia group and 93 in the non-hyperthermia group. In the overall cohort, RFH was associated with longer median PFS (10.17 vs. 7.06 months; HR = 0.70; p = .011) and median OS (19.31 vs. 14.98 months; HR = 0.71; p = .018). ORR did not differ significantly between groups (21.0% vs. 21.5%; p = .930), whereas DCR was higher with RFH (96.6% vs. 86.0%; p = .005). After PSM, 168 patients were matched; balance improved, but residual imbalance remained. Matched-cohort estimates remained directionally similar for PFS (9.72 vs. 7.09 months; HR = 0.67; p = .013) and OS (19.02 vs. 15.12 months; HR = 0.67; p = .015). Recorded grade ≥3 immune-related adverse events occurred in 5.0% and 4.3% of patients, respectively. RFH-related events were mainly transient local skin erythema and induration, and no RFH-related serious adverse events were recorded. RFH added to ICIs and chemotherapy was associated with longer PFS and OS, requiring confirmation in prospective randomized studies.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: